The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $24,784,877 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 159 grants at over 100 hospitals in 29 countries.




CONNECT Consortium - $278,619

Amount
$278,619.00
Date
September 2021

Immuno-Modulation to Treat Poor-Prognosis Pediatric Brain Tumors

Institute of Cancer Research – $113,747

Amount
$113,747.00
Date
September 2021

Co-Culture Disruptor Screens to Target Cell-Cell Interactions in DMG

Institute of Cancer Research – $498,716

Amount
$498,716.00
Date
September 2021

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) - An International Connect Consortium Preclinical / Clinical

Sydney Children’s Hospital – $195,327

Amount
$195,327.00
Date
September 2021

Phase I/II Study of Oral DFMO and AMXT1501 for DIPG/DMG

Children’s Hospital of Colorado – $200,000

Amount
$200,000.00
Date
September 2021

Multimodality, Combination Treatment Strategy for DIPG/DMG

Children's Cancer Institute – $50,000

Amount
$50,000.00
Date
September 2021

Developing Novel Combination Therapies for Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital – $200,000

Amount
$200,000.00
Date
September 2021

Targeting Purine Synthesis and One Carbon Metabolism in DIPG

UPMC Children's Hospital – $50,000

Amount
$50,000.00
Date
September 2021

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance

University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
September 2021

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma

Duke University Hospital – $50,000

Amount
$50,000.00
Date
September 2021

Identifying Oncolytic Viral Therapy Resistance Mechanisms in Brain Tumors

Funding of PBTCF 2021: PBTC-059 - $25,000

Amount
$25,000.00
Date
January 2021

Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma

International DIPG/DMG Registry And Repository - $1,508,198

Amount
$1,508,198.00
Date
December 2020

Children's Cancer Institute - $99,251

Amount
$99,251.00
Date
September 2020

Discovering New Epigenetic Players in DIPG Oncogenesis

Northwestern Memorial Hospital - $110,000

Amount
$110,000.00
Date
September 2020

Development of Histone Demethylase Inhibitor Against DIPG

The Hospital for Sick Children - $100,000

Amount
$100,000.00
Date
September 2020

Methionne Deptrivation as a Therapeutic Strategy for Diffuse Intrinsic Pontine Glioma